2. GPCR/G Protein
  3. P2Y Receptor
  4. NF340

NF340 is a P2Y11 receptor inhibitor with a pIC50 of 7.3-7.7 against human P2Y11 receptor, and it exhibits high selectivity over other P2Y family receptors. NF340 binds to the ATP-binding amino acid residues of the P2Y11 receptor to inhibit its activity, block nociceptive activity, and reduce spinal dorsal horn P2Y11 receptor upregulation induced by spinal cord injury. NF340 attenuates the NFκB signaling pathway activated by IL-1β by decreasing IκBα phosphorylation, nuclear p65 accumulation and NFκB promoter activity. NF340 inhibits IL-1β-induced pro-inflammatory cytokine expression, reduces intracellular ROS and 4-HNE levels, and suppresses IL-1β-induced matrix metalloproteinase expression in primary fibroblast-like synoviocytes. NF340 inhibits ATP-induced elevation of intracellular calcium 2+ concentration and cell migration in human hepatocellular carcinoma cells. NF340 is applicable to the research of neuropathic pain, myocardial ischemia/reperfusion injury, inflammatory pain, rheumatoid arthritis and hepatocellular carcinoma.

For research use only. We do not sell to patients.

NF340

NF340 Chemical Structure

CAS No. : 202982-98-7

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

NF340 Related Antibodies

Top Publications Citing Use of Products

View All P2Y Receptor Isoform Specific Products:

View All Isoforms
P2Y1 Receptor P2Y2 Receptor P2Y6 Receptor P2Y11 Receptor P2Y12 Receptor P2Y13 Receptor P2Y14 Receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

NF340 is a P2Y11 receptor inhibitor with a pIC50 of 7.3-7.7 against human P2Y11 receptor, and it exhibits high selectivity over other P2Y family receptors. NF340 binds to the ATP-binding amino acid residues of the P2Y11 receptor to inhibit its activity, block nociceptive activity, and reduce spinal dorsal horn P2Y11 receptor upregulation induced by spinal cord injury. NF340 attenuates the NFκB signaling pathway activated by IL-1β by decreasing IκBα phosphorylation, nuclear p65 accumulation and NFκB promoter activity. NF340 inhibits IL-1β-induced pro-inflammatory cytokine expression, reduces intracellular ROS and 4-HNE levels, and suppresses IL-1β-induced matrix metalloproteinase expression in primary fibroblast-like synoviocytes. NF340 inhibits ATP-induced elevation of intracellular calcium 2+ concentration and cell migration in human hepatocellular carcinoma cells. NF340 is applicable to the research of neuropathic pain, myocardial ischemia/reperfusion injury, inflammatory pain, rheumatoid arthritis and hepatocellular carcinoma[1][2][3][4][5].

IC50 & Target

P2Y11 Receptor

 

In Vitro

NF340 inhibits the P2Y11R-mediated modulation of adult ventricular human CF secretome, abolishing the NF546-induced reduction in human DC maturation marker expression and reducing the NF546-induced protective effect on human cardiomyocyte viability after simulated I/R injury[2].
NF340 is a selective antagonist of human P2Y11 receptors, with a pEC50 of 7.3-7.7, showing 1000-fold lower potency at other human P2Y receptor subtypes[3].
NF340 (10-20 μM; 24 h) dose-dependently inhibits IL-1β-induced TNF-α and IL-6 expression at both mRNA and protein levels in human fibroblast-like synoviocytes, with 20 μM NF340 exerting a stronger inhibitory effect than 10 μM NF340[4].
NF340 (10-20 μM; 24 h) dose-dependently inhibits IL-1β-induced MMP-1, MMP-3, and MMP-13 expression at both mRNA and protein levels in human fibroblast-like synoviocytes, with 20 μM NF340 exerting a stronger inhibitory effect than 10 μM NF340[4].
NF340 (10-20 μM; 24 h) dose-dependently ameliorates IL-1β-induced oxidative stress in human fibroblast-like synoviocytes, as measured by reduced cellular ROS and 4-HNE levels, with 20 μM NF340 exerting a stronger inhibitory effect than 10 μM NF340[4].
NF340 (10-20 μM; 6 h (p-IκBα assay); 24 h (nuclear p65 and luciferase assays)) dose-dependently inhibits IL-1β-induced NF-κB activation in human fibroblast-like synoviocytes, as measured by reduced IκBα phosphorylation, nuclear p65 accumulation, and NF-κB promoter activity, with 20 μM NF340 exerting a stronger inhibitory effect than 10 μM NF340[4].
NF340 (10 μM; 5 min) potently inhibits ATP-induced intracellular calcium elevation in Huh-7 human hepatocellular carcinoma cells[5].
NF340 (10 μM; 5 min) significantly reduces NF546-induced intracellular calcium elevation in HepG2 human hepatocellular carcinoma cells[5].
NF340 (10 μM; 24 h) completely blocks ATP-induced migration of Huh-7 human hepatocellular carcinoma cells without affecting basal migration[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NF340 Related Antibodies

Real Time qPCR[4]

Cell Line: human fibroblast-like synoviocytes (FLS)
Concentration: 10 μM, 20 μM
Incubation Time: 24 h
Result: Reduced IL-1β-induced TNF-α mRNA expression from 5.8-fold to 3.5-fold at 10 μM, and to 2.2-fold at 20 μM.
Reduced IL-1β-induced IL-6 mRNA expression from 4.5-fold to 3-fold at 10 μM, and to 1.5-fold at 20 μM.
Reduced IL-1β-induced TNF-α protein induction from 5-fold to 3-fold at 10 μM, and to 1.7-fold at 20 μM.
Reduced IL-1β-induced IL-6 protein induction from 4.2-fold to 2.8-fold at 10 μM, and to 1.5-fold at 20 μM.\nReduced IL-1β-induced MMP-1, MMP-3, and MMP-13 mRNA expression from 5-6-fold to 3-fold at 10 μM, and to 2-fold at 20 μM.
Reduced IL-1β-induced MMP-1, MMP-3, and MMP-13 protein expression from 4-5-fold to 3-fold at 10 μM, and to 2-fold at 20 μM.

Western Blot Analysis[4]

Cell Line: human fibroblast-like synoviocytes (FLS)
Concentration: 10 μM (p-IκBα assay); 20 μM (p-IκBα assay); 10 μM (nuclear p65 and luciferase assays); 20 μM (nuclear p65 and luciferase assays)
Incubation Time: 6 h (p-IκBα assay); 24 h (nuclear p65 and luciferase assays)
Result: Reduced IL-1β-induced p-IκBα phosphorylation from 5-fold to 3.5-fold at 10 μM (6 h), and to 2-fold at 20 μM (6 h).
Reduced IL-1β-induced nuclear p65 accumulation from 3.2-fold to 2-fold at 10 μM (24 h), and to 1.5-fold at 20 μM (24 h).
Reduced IL-1β-induced NF-κB luciferase promoter activity from 80-fold to 50-fold at 10 μM (24 h), and to 25-fold at 20 μM (24 h).
In Vivo

NF340 (0.3-30 μM; i.t.; single bolus injection; 6-hour assessment period; 30 μM; i.t.; every 12 hours; 3 days) produces dose-dependent antiallodynic effects in neuropathic rats and reverses spinal nerve injury-induced up-regulation of spinal P2Y11 receptors, indicating spinal P2Y11 receptors participate in maintaining neuropathic pain[1].
NF340 (1-10 nmol/paw; s.c.; 10 minutes before formalin injection) produces peripherally localized antinociception in the second phase of formalin-induced inflammatory pain in female Wistar rats[3].
NF340 (1 nmol/paw; s.c.; co-administered with P2Y11 receptor agonists; 10 minutes before formalin injection) blocks P2Y11 agonist-induced pronociception in formalin-induced inflammatory pain in female Wistar rats[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar rats (female, 140-180 g, left L5 and L6 spinal nerve ligation)[1]
Dosage: 0.3 μM (single injection antiallodynia); 10 μM (single injection antiallodynia); 30 μM (single injection antiallodynia; repeated injection P2Y11 regulation)
Administration: i.t.; single bolus injection; 6-hour assessment period; i.t.; every 12 hours; 3 days
Result: Produced significant, dose-dependent antiallodynic effects, increasing 50% paw withdrawal thresholds in spinal nerve ligated rats, with maximal effect reached at ~1 hour and decaying gradually over 6 hours.
Reversed spinal nerve injury-induced up-regulation of P2Y11 receptor expression in the ipsilateral dorsal spinal cord, reducing relative P2Y11/β-actin intensity from ~1.4 to ~0.4.
Animal Model: Wistar rats (female, 8-10 weeks old, 180-200 g, inflammatory pain model via 1% formalin injection)[3]
Dosage: 1 nmol/paw; 10 nmol/paw
Administration: s.c.; 10 minutes before formalin injection
Result: Significantly reduced 1% formalin-induced flinching behavior during the second phase (15-60 minutes) of the test.
Did not affect formalin-induced nociception in any phase when administered contralaterally.
Animal Model: Wistar rats (female, 8-10 weeks old, 180-200 g, inflammatory pain model via 0.5% formalin injection)[3]
Dosage: 1 nmol/paw
Administration: s.c.; co-administered with P2Y11 receptor agonists, 10 minutes before formalin injection
Result: Prevented the pronociceptive effect induced by ATP (1000 nmol/paw) in both phases of the formalin test.
Prevented the pronociceptive effect induced by NF546 (3 nmol/paw) during the second phase of the test.
Did not modify 0.5% formalin-induced nociceptive behavior when administered alone at this dose.
Molecular Weight

986.84

Formula

C37H26N4Na4O15S4
CAS No.
SMILES

O=C(NC1=CC(C(NC2=C3C=C(S(=O)(O[Na])=O)C=CC3=CC(S(=O)(O[Na])=O)=C2)=O)=CC=C1C)NC4=CC(C(NC5=C6C=C(S(=O)(O[Na])=O)C=CC6=CC(S(=O)(O[Na])=O)=C5)=O)=CC=C4C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

NF340 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NF340202982-98-7NF 340NF-340P2Y Receptorfibroblast-like synoviocytesNFκB signalingdendritic cellIκBα phosphorylationdorsal spinal cordP2Y11 receptorcardiomyocytesspinal nerve ligated ratshuman hepatocellular carcinoma cellscardiac fibroblastInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
NF340
Cat. No.:
HY-108659
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.